8-K/A: Aditxt Amends Acquisition Agreement, Files Pro Forma Financials for Appili and Evofem

Aditxt, Inc. has amended its acquisition agreement with Appili Therapeutics and filed pro forma financial statements reflecting the acquisitions of both Appili and Evofem Biosciences.

Summary

• Aditxt, Inc. has filed an amendment to its previous reports regarding the acquisition of Appili Therapeutics, Inc.
• The amendment includes the required historical financial statements of Appili and pro forma financial information.
• The acquisition of Appili is structured as a statutory plan of arrangement under the Canada Business Corporation Act.
• The agreement has been amended multiple times, extending the outside date for the deal to September 30, 2024.
• Aditxt is required to use commercially reasonable efforts to complete financing by September 15, 2024.
• The pro forma financial information is for informational purposes only and does not represent actual or future results.
• The document includes audited financial statements for Appili as of March 31, 2024 and 2023.
• It also includes unaudited pro forma combined financial information as of March 31, 2024, and December 31, 2023, giving effect to the acquisitions of Evofem and Appili.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the acquisition could be positive for Aditxt, Appili's poor financial health and the uncertainty around financing raise concerns. The delays in the acquisition process also contribute to a negative sentiment.

Positives

• The document provides detailed financial information for Appili, allowing investors to assess the company's performance.
• The pro forma financials give an indication of the potential combined financial position of Aditxt, Evofem, and Appili.
• The acquisition of Appili could provide Aditxt with new technologies and market opportunities.

Negatives

• Appili has a significant accumulated deficit of $69,093,116 as of March 31, 2024.
• Appili's cash balance has decreased significantly year-over-year.
• Appili's auditors have raised concerns about the company's ability to continue as a going concern.
• The acquisition is contingent on Aditxt securing financing by September 15, 2024, which introduces uncertainty.

Risks

• Appili's ability to continue as a going concern is uncertain, as noted by its auditors.
• The acquisition is dependent on Aditxt securing financing, which may not be successful.
• The pro forma financial information is not indicative of future results and may not reflect the actual performance of the combined entity.
• The integration of Appili and Evofem into Aditxt may present challenges and risks.
• The transaction could be terminated if financing is not completed by the deadline.

Future Outlook

The document states that the pro forma financial information is for informational purposes only and does not project future results. The acquisition is expected to close in Q3 2024, subject to approvals and financing.

Industry Context

This announcement reflects a trend of consolidation in the biopharmaceutical industry, where companies seek to expand their pipelines and market reach through acquisitions. The acquisition of Appili by Aditxt is part of a larger strategy that also includes the acquisition of Evofem.

Comparison to Industry Standards

• Appili's financial performance, particularly its significant losses and declining cash balance, is not uncommon for early-stage biopharmaceutical companies.
• Many companies in this sector rely on external funding and partnerships to advance their research and development programs.
• The pro forma financials, while not predictive, provide a benchmark for the combined entity's potential performance compared to industry peers.
• The acquisition of Appili and Evofem by Aditxt is similar to other strategic acquisitions in the biopharma space, where companies seek to leverage synergies and expand their product portfolios.
• Comparable companies in the biopharma sector often have similar challenges with profitability and cash flow, especially during the development phase.

Related Party Transactions

• The document mentions a bridge loan from Bloom Burton, a related party, to Appili.

Stakeholder Impact

• Shareholders of Appili will receive Aditxt shares and cash as part of the acquisition.
• Employees of Appili may experience changes as a result of the acquisition.
• The acquisition could impact the future development and commercialization of Appili's products.
• Creditors of Appili will be impacted by the assumption of liabilities by Aditxt.

Next Steps

• Aditxt needs to secure the required financing by September 15, 2024.
• Appili shareholders need to approve the transaction.
• The transaction needs to receive court, regulatory, and stock exchange approvals.
• The acquisition is expected to close in calendar Q3 2024.

Key Dates

Keywords

acquisition, Aditxt, Appili Therapeutics, Evofem Biosciences, pro forma financials, merger, financing, arrangement agreement, financial statements, biopharmaceutical